1 / 9

Oral Poster Discussion Session Room 3 Wednesday 20 July, 13:00-14:00

Oral Poster Discussion Session Room 3 Wednesday 20 July, 13:00-14:00 Co-Chairs: Mark A. Waimberg, Canada Christophe Vanpuille, United States 13:00 Introduction M.Andreoni, Italy 13:05 Explaining the CAPRISA 004 results: Tenofovir as a double-targeted HIV-1/HSV-2 antiviral

bevis
Télécharger la présentation

Oral Poster Discussion Session Room 3 Wednesday 20 July, 13:00-14:00

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Oral Poster Discussion Session Room 3 Wednesday 20 July, 13:00-14:00 Co-Chairs: Mark A. Waimberg, Canada Christophe Vanpuille, United States 13:00 Introduction M.Andreoni, Italy 13:05 Explaining the CAPRISA 004 results: Tenofovir as a double-targeted HIV-1/HSV-2 antiviral A. Graciela, A. Lisco, C. Vanpouille, E. Balestra, J. van den Oord, T. Cihlar, C.-F. Perno, R. Snoeck, L. Margolis, J. Balzarini. Belgium, United States, Italy 13:10 HIV-1 escape from the CCR5 antagonist maraviroc associated with an altered and less efficient mechanism of gp120-CCR5 engagement that attenuates macrophage tropism M. Roche, M.R. Jakobsen, J. Sterjovski, A. Ellett, F. Posta, B. Lee, B. Jubb, M. Westby, S.R. Lewin, P.A. Ramsland, M.J. Churchill, P.R. Gorry. Australia, United States, United Kingdom. 13:15 HIV-1 evolution and drug-resistance among patients receiving antiretroviral therapy (ART) in san Matteo Country, california, 1997-2010 S. Dalai, S. Sethi, V. Levy, D. Katzenstein. United States 13:20 Autologous T-cell therapy based on a lentiviral vector expressing long antisense RNA targeted against HIV- 1 env gene influences HIV replication and evolution in vivo A. Pasternak, N. Korokhov, B. Berkhout, V. Lukashov, L. Humeau. Netherlands, United States 13:25 Effects of HIV integrase polymorphisms on raltegravir-resistance susceptibility H. Suzuki, M. Maejima, J. Hattori, M. Nishizawa, S. Ibe, Y. Yokomaku, Y. Iwatani, W. Sugiura. Japan 13:30 Moderated discussion

  2. Main topics addressed by this oral poster discussion Antiviral activity of antiretroviral drugs Antiherpetic activity of tenofovir Lamivudine HBV Emtricitabine HBV Tenofovir HBV Indinavir HHV-8

  3. Maintopicsaddressedbythisoral poster discussion Antiviralactivityofantiretroviraldrugs Drugresistanceof HIV

  4. MVCres gp120 New mechanism of resistance to Maraviroc MVCres Virus MVCsens Virus gp120 binding site on CCR5 Mutated gp120 recognizes CCR5 differently Free receptor wt gp120 Binding sitedisruptedby maraviroc Binding siteNOT disruptedby maraviroc MVC (•) bound to CCR5 No Entry Mori J, et al. IHIVDRW, 2007. Abstract 10.

  5. Q148 S153 G140 E138 N155 T66 F121 Mg V72 T125 Effect of Integrase polymorphisms on RAL-resistance acquisition • In naïve patients polymorphisms in Integrase gene is common but resistance-conferring mutations is rare to nonexistent

  6. Selection and evolution of HIV drug resistance during ART ART

  7. Maintopicsaddressedbythisoral poster discussion Antiviralactivityofantiretroviraldrugs Drugresistanceof HIV T-celltherapy

  8. The effects of therapy with autologous genetically modified CD4 T-lymphocytes

  9. Thank You for your attention

More Related